What is HC Wainwright’s Estimate for KALV FY2027 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a report released on Thursday, March 12th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings per share of $0.84 for the year, up from their previous forecast of $0.82. HC Wainwright currently has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

Other equities research analysts have also issued reports about the stock. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Needham & Company LLC lifted their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $29.40.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV traded up $0.35 during midday trading on Friday, hitting $17.73. 30,928 shares of the company’s stock were exchanged, compared to its average volume of 995,150. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The business’s fifty day moving average price is $15.73 and its two-hundred day moving average price is $14.24. The company has a market cap of $896.00 million, a price-to-earnings ratio of -4.47 and a beta of -0.35. KalVista Pharmaceuticals has a 12-month low of $9.23 and a 12-month high of $19.00.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 6,693 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a total transaction of $107,623.44. Following the completion of the sale, the chief executive officer directly owned 451,815 shares in the company, valued at $7,265,185.20. This represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Brian Piekos sold 1,767 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the sale, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. The trade was a 11.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 33,378 shares of company stock worth $522,290. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $55,000. Wolverine Asset Management LLC purchased a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $57,000. KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at approximately $63,000. Finally, Truvestments Capital LLC lifted its holdings in KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.